Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You may be right and if you are then I hope it is a good reason! I have read in several places that competition for leases is fierce. One thing is for sure, I EXPECT them to hit oil. I just don't know that I want other companies or land owners knowning how much until we are done accumulating leases. Maybe the company will let us know the reason soon.
I think they are still actively pursuing new leases and if they are then it is not wise to announce how successful their drilling efforts are. It only raises the cost of new leases and brings in competition. I have heard this on other O & G boards before and I think NVMG has alluded to it before also. I certainly hope that is the reason!
Ignis Petroleum Group, Inc. Completes Purchase of Interests in Barnett Shale Acreage, Producing Wells, Development Program and Gas Gathering & Treating System
Wednesday November 15, 6:35 pm ET
DALLAS, TX--(MARKET WIRE)--Nov 15, 2006 -- Ignis Petroleum Group, Inc. (OTC BB:IGPG.OB - News), an oil and gas company with operations focused on the acquisition, exploration and development of crude oil and natural gas positions in the onshore U. S. Gulf Coast and Mid-Continent areas, today announced that it has completed its previously announced acquisition from W. B. Osborn Oil & Gas Operations, Ltd. ("WBO") and St. Jo Pipeline Limited of 45% of the acreage, producing properties, and natural gas gathering and treating system within the St. Jo Ridge (Barnett Shale) Field, located in Montague and Cooke Counties, Texas. The effective date of the transaction is June 1, 2006.
ADVERTISEMENT
Specifically, the acquisition includes 45% of WBO's interests in 7,890 gross acres (6,864 net acres), 13 producing wells, and estimated total net proved reserves of 1.11 million barrels of oil equivalent (Mboe) of which 0.45 Mboe are proved developed producing as of June 1, 2006. These estimates of proved reserves do not include probable and possible reserve categories. Approximately 66% of the proved reserves are oil and condensate and 34% are natural gas. The gathering and treating system consists of a 100% interest in approximately 24 miles of gathering lines, which accumulates and treats natural gas at a central plant. WBO has identified 36 initial drilling locations on the acreage before beginning the infill-drilling program, which could yield more than 100 additional drilling sites. A Pioneer Drilling Company rig, secured under a 12-month renewable contract, is currently being used to carry out the continuous drilling program. This continuous drilling program has completed 6 gross wells (5.25 net) since the effective date of which 4 are producing oil and gas and 2 are in various stages of completion.
The acquired interests are held and managed by Ignis Barnett Shale, LLC ("IB"), which is owned by Ignis Petroleum Group, Inc. ("IGPG"), and affiliates of Silver Point Capital. Under the terms of IB's limited liability company agreement, the Silver Point affiliates funded the transaction and will fund future acreage acquisitions and development costs. IGPG can earn up to 50% of the cash distributions of IB after certain performance criteria are met. WBO will continue to own 55% of the program and assets, and will continue to be the operator.
Michael P. Piazza, Ignis President and Chief Executive Officer, said, "We are pleased to complete this strategic acquisition and development project as we continue to focus on achieving our long-term growth targets. Our operating partner in this project, WBO, a private San Antonio, Texas-based Company, has a long history of developing and producing oil and gas. We believe the Ignis team will bring seasoned expertise and advancements in new technology to enhance recovery from the project, working alongside our partners."
About Ignis Petroleum
Ignis Petroleum Group, Inc. is a Dallas-based oil and gas production company focused on exploration, acquisition and development of crude oil and natural gas reserves in the United States. The Company's management has closely aligned itself with strategic industry partnerships and is building a diversified energy portfolio. It focuses on prospects that result from new lease opportunities, new technology and new information. For further information, visit www.ignispetro.com.
Safe Harbor for Forward-Looking Statements
This release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation, expectations, beliefs, plans and objectives regarding the potential transactions and ventures discussed in this release. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are the risks inherent in oil and gas exploration, the need to obtain additional financing, the availability of needed personnel and equipment for the future exploration and development, fluctuations in gas prices, and general economic conditions.
Contact:
For Investor & Media Inquiries, contact:
Patty Dickerson
Vice-President External Affairs
214-459-3193
866-67-IGNIS (866-674-4647)
pd@ignispetroleum.com
We have been on a slow simmer for awhile. I think soon we may boil over. Last time we ran to .036 on virtually nothing. I hope we move up slow and steady this time and maybe we can maintain the PPS better. There are so many irons in the fire, its just a matter of time.
Here is the PR.....
Hollis-Eden Pharmaceuticals Provides Update on Final Stages of Negotiations for BioShield Procurement Contract
Friday November 3, 7:00 am ET
SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH - News) today provided an update on its progress in negotiations with the Department of Health and Human Services (HHS) on a potential BioShield procurement contract for NEUMUNE®, the Company's lead drug candidate for Acute Radiation Syndrome (ARS).
ADVERTISEMENT
As previously announced, Hollis-Eden was informed by HHS in late June that the Company "is within the competitive range for discussion and further evaluation" on a potential procurement contract for NEUMUNE. Hollis-Eden has been engaged since then in ongoing productive negotiations with HHS and has recently been advised that the Company is still in the competitive range for an ARS contract award. Hollis-Eden is not aware of any other company that remains in the competitive range for this contract award.
As a follow-up to a face-to-face meeting with HHS last week, Hollis-Eden received a letter from HHS yesterday indicating that after request and receipt of the Company's final proposal revisions, the government must complete numerous steps internally prior to proceeding to a contract award. Noting these considerations, HHS indicated in its letter a tentative award date of January 31, 2007. Successful completion of these negotiations and the award of an ARS contract would mark the first-ever procurement by the U.S. government of a drug developed specifically to treat ARS, a life-threatening condition resulting from exposure to high levels of radiation.
About Hollis-Eden
Hollis-Eden Pharmaceuticals, Inc. is developing a proprietary new class of small molecule compounds that are metabolites or synthetic analogs of adrenal steroid hormones. These compounds, designed to restore the biological activity of cellular signaling pathways disrupted by disease and aging, have been demonstrated in humans to possess several properties with potential therapeutic benefit - they regulate innate and adaptive immunity, reduce nonproductive inflammation and stimulate cell proliferation. The Company's lead product candidate, NEUMUNE, is entering late-stage development for the treatment of Acute Radiation Syndrome (ARS), a life-threatening condition resulting from exposure to high levels of radiation following a nuclear or radiological incident, and is being explored for use in combating healthcare-associated infections. Hollis-Eden also is profiling optimized second-generation compounds for potential clinical development in a broad spectrum of therapeutic categories including hematology, metabolic disorders, autoimmune disorders, pulmonary diseases, oncology and infectious diseases. For more information on Hollis-Eden, visit the Company's website at www.holliseden.com.
This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, the potential and prospects of the Company's drug discovery program and its drug candidates. Any statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause the Company's actual results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such statements are subject to certain risks and uncertainties inherent in the Company's business, including, but not limited to: the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the ability to obtain regulatory approval for NEUMUNE under the U.S. Food and Drug Administration Animal Efficacy Rule, even if shown to be effective in preclinical studies; the ability to receive any stockpiling orders for NEUMUNE from the U.S. federal, state and foreign governments or agencies, even if approved by regulatory authorities; the Company's future capital needs; the Company's ability to obtain additional funding; the ability of the Company to protect its intellectual property rights and to not infringe the intellectual property rights of others; the development of competitive products by other companies; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update or revise the information contained in this press release as a result of new information, future events or circumstances arising after the date of this press release.
Contact:
Hollis-Eden Pharmaceuticals
Dan Burgess, Chief Operating Officer and CFO
Scott Rieger, Director, Corporate Communications
858-587-9333
Source: Hollis-Eden Pharmaceuticals, Inc.
Sorry about not updating the IBOX. I have been following a couple of nice runners lately. There was a PR released a week ago or so that said that the deadline had been extended. I will look for it today and update the IBOX. My impression is that it could still possibly happen sooner but the HHS has the option of extending until the end of Jan.
I have not seen Hollis-Eden actually mentioned anywhere. I get solicitation notices for newsletters where they say they will tell me the name of the company if I subscribe. Looking at the description I am sure it is HEPH.
I hope so for the longs. My options went from green to .05 in one day. At this point I will hold on because it is not worth selling for a nickel. With the deadline pushed back to Jan the odds are now against them being in the money.
Actually I have some in a second account that is still red too but like you, a whole lot less red...
I think my account finally went green on this one!eom
I have been here to long for a piddaly double...eom
I have heard of Stansberry Research. They seem to be loosely affiliated with the Oxford Club. That is one of the expensive newsletters that I mentioned. I have not heard of the website you mentioned. I am sure it does exist but I have never looked for it.
If you mean Oxford Club...the push I mentioned comes from them selling newsletters. Sometimes it seems they are just in the business of selling newsletters. They will send an advertisement saying some company is about to do a big deal and if you sign up for the newsletter they will tell you its name. Most of the time I have been able to figure out who they are talking about. A couple of months ago the company was Hollis-Eden before the Sep 15 deadline. I just recently got another email and it looks like it is pushing Hollis-Eden again before the Nov 30 deadline. I think their portfolios do pretty well but I have never taken any of the newsletters. They are generally very expensive to me. I have never had a lot of luck with newsletters. They usually take away what they give me eventually.
b/a 6.61 / 6.75 Last sell 6.75
Probably, they pushed this hard a couple of months ago and looks like they are starting again.
If this is true my options may expire before they come into the money.
AP Hollis Eden Could Get Neumune Contract
Friday November 3, 8:54 am ET
Hollis Eden Says Within Range of Getting Neumune National Stockpile Contract
SAN DIEGO (AP) -- Drug developer Hollis-Eden Pharmaceuticals Inc. said it could get a government contract to make a drug for radiation sickness by the end of January.
The company said late Thursday it is in the lead in a bid for a Department of Health and Human Services contract to make its Neumune drug part of the national stockpile for the treatment of acute radiation syndrome.
The HHS said Hollis-Eden "is within the competitive range for discussion and further evaluation" for the contract. Hollis-Eden said it is not aware of another competitor within range of getting the contract.
The agency set a tentative award date of Jan. 31.
I think the Oxford club is starting its ARS push again. They don't mention Hollis-Eden but I don't think there is any doubt that is who they are talking about.
I agree with Lowman. All of my posts concerning this stock have stated that this is my big play for 2007. If it happens earlier then I will be happy. I sold my entire postion in the last runup after the Shell PR because I thought it was much ado about nothing. I have since bought back in lower. This company will take off. I don't know when but I will be there when it does.
Hollis-Eden Pharmaceuticals Announces Third Quarter 2006 Conference Call and Investor Conference Webcasts
Wednesday November 1, 7:00 am ET
SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH - News) today announced that it has scheduled the following conference call and webcasts:
* Third Quarter 2006 Conference Call and Webcast November 3, 2006 at 2:00 p.m. Eastern (11:00 a.m. Pacific). Hollis-Eden will release financial results prior to the market opening that day. The conference call can be accessed by dialing 866-362-4829 (domestic) or 617-597-5346 (international) and requesting the Hollis-Eden conference call. A live webcast of the conference call will be available under "Event Calendar" on the Investors section of Hollis-Eden's website at www.holliseden.com. The webcast will be archived at the Company's website for 30 days, and a replay of the call will be available by phone for 24 hours beginning approximately one hour after the call is completed, and can be accessed at 888-286-8010 (domestic) or 617-801-6888 (international), passcode 66212232.
* Rodman and Renshaw 8th Annual Healthcare Conference in New York on November 7, 2006, 2:50 p.m. Eastern (Daniel D. Burgess, Chief Operating Officer and CFO, presenting.) A live webcast will be available from this conference, and may be accessed under "Event Calendar" on the Investors section of Hollis-Eden's website at www.holliseden.com. The webcast will be archived at the Company's website for 30 days.
* BIOCOM Investor Conference in San Diego on November 15, 2006, 10:20 a.m. Pacific. A live webcast will be available from this conference, and may be accessed under "Event Calendar" on the Investors section of Hollis-Eden's website at www.holliseden.com.
About Hollis-Eden
Hollis-Eden Pharmaceuticals, Inc. is developing a proprietary new class of small molecule compounds that are metabolites or synthetic analogs of adrenal steroid hormones. These compounds, designed to restore the biological activity of cellular signaling pathways disrupted by disease and aging, have been demonstrated in humans to possess several properties with potential therapeutic benefit -- they regulate innate and adaptive immunity, reduce nonproductive inflammation and stimulate cell proliferation. The Company's lead product candidate, NEUMUNE® (HE2100), is entering late-stage development for the treatment of Acute Radiation Syndrome (ARS), a life-threatening condition resulting from exposure to high levels of radiation following a nuclear or radiological incident, and is being explored for use in combating healthcare-associated infections. Hollis-Eden also is profiling optimized second-generation compounds for potential clinical development in a broad spectrum of therapeutic categories including hematology, metabolic disorders, autoimmune disorders, pulmonary diseases, oncology and infectious diseases. For more information on Hollis-Eden, visit the Company's website at www.holliseden.com.
This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, the potential and prospects of the Company's drug discovery program and its drug candidates. Any statement included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause the Company's actual results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such statements are subject to certain risks and uncertainties inherent in the Company's business, including, but not limited to: the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the ability to obtain regulatory approval for NEUMUNE under the U.S. Food and Drug Administration Animal Efficacy Rule, even if shown to be effective in preclinical studies; the ability to receive any stockpiling orders for NEUMUNE from the U.S. federal, state and foreign governments or agencies, even if approved by regulatory authorities; the Company's future capital needs; the Company's ability to obtain additional funding; the ability of the Company to protect its intellectual property rights and to not infringe the intellectual property rights of others; the development of competitive products by other companies; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update or revise the information contained in this press release as a result of new information, future events or circumstances arising after the date of this press release.
Contact:
Hollis-Eden Pharmaceuticals
Dan Burgess, Chief Operating Officer and CFO
Scott Rieger, Director, Corporate Communications
858-587-9333
Source: Hollis-Eden Pharmaceuticals, Inc.
I didn't think so either, but during the USSEC demo, John mentioned that the old diesel engine they are running came from a CastCrete truck...lol.
Same here. I intended to average down but didn't have the cash available. Still holding .....
Mine was August too...but I will take a late birthday present. eom
Slow for me. We picked up a lot of new investors over the weekend, lol.
WOW, anyone know what is happening. At .11 now, nearly 1.4mm volume.
The volume today is over the 10day average now and the pps has gone up .02. I hope somthing is up.
My post was just a quick note to hopefully stimulate some interest. The interview was interesting and there were several other things I need to hear again. I am at work and couldn't pay as close attention as I would have liked.
I wondered if the rigs had been mentioned before. I hope they receive them soon. It looks like they already have wells to rework.
A couple of observations concerning the interview…
Some of this was has already been in PR’s but I don’t remember exactly which ones (too many positions to follow).
In negotiations for a large field that has current production and many shutins.
Their 6mo goal is 1000bopd. Apparently they do currently have production and are selling oil. Hopefully we will get some numbers soon.
One thing I don’t remember reading anywhere, they are expecting delivery of two fully customized workover rigs.
They mentioned that the panels were concrete filled steel panels. I have not been able to find anything on Eurowest Panel Homes.
I will try to listen again when I can give it my undivided attention.
Press Release Source: Native American Energy Group, Inc.
Native American Energy Interviewed on WallSt.net
Wednesday October 25, 9:45 am ET
FOREST HILLS, N.Y.--(BUSINESS WIRE)--Native American Energy Group, Inc. (OTC Pink Sheets: NVMG - News) -- On Oct. 24, 2006, Joseph D'Arrigo, CEO, and Raj Nanvaan, CFO of Native American Energy Group, Inc. updated the investment community in an all-new, exclusive interview with www.wallst.net.
Questions included:
* Can you give us a brief overview of the Company, what you do, and your target markets?
* What are some trends in the market that you think bolster the Company's prospects for near-term growth? (6-12 months) And has the Company laid the groundwork for long-term growth?
* What do you think gives your Company a competitive edge in the market place?
* What are some milestones over the next 12 - 18 months that investors should watch for?
To hear the interview in its entirety, visit www.wallst.net, and click on "Interviews." Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the respective company's ticker symbol in the Search Archive window.
About Native American Energy Group, Inc. (OTC Pink Sheets:NVMG - News) http://www.nativeamericanenergy.com/aboutus.htm
Safe Harbor Statement: This News Release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and section 21E of the United States Securities & Exchange Act of 1934, as amended, with respect to corporate objectives, projections, estimates, operations, acquisition and development of various interests and certain other matters. These statements are made under the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.
Contact:
Native American Energy Group, Inc.
Richard Ross, 800-780-8076
ir@nativeamericanenergy.com
http://www.nativeamericanenergy.com
I found a reference to Amgen and HHS here.
http://www.signonsandiego.com/uniontrib/20060207/news_1b7hollis.html
This article, dated 02/07/2006, says that HHS appeared to favor Amgen’s drug Neupogen but there is some question as to its effectiveness in a mass casualty scenario. I can’t find any more references to Amgen or Neupogen. The Amgen website doesn’t mention anything about responding to a HHS RFP and there is no reference to Project Bioshield.
In this article, dated 8/15/2006, Hollis-Eden and Novelos are the only two companies listed as judged by HHS to be “within competitive range” for further discussion.
http://www.govexec.com/features/0806-15/0806-15na2.htm
In this article found by kmp9643, dated 10/24/2006, Novelos’ proposal was bypassed by HHS.
http://www.genengnews.com/news/bnitem.aspx?name=7459458
So far, it looks like HEPH may be the only company left and the fact that Novelos was eliminated might mean a decision is close?? I will keep looking for information.
You may be right. HEPH is now over 6.90. We may break $7 today or tomorrow. It might just take time to sink in that HEPH may be all that is left.
I can't remember who else was in the running but I will try to find out tonight and put in the ibox.
I have been in this one over a year now. I guess I will go down in flames with it or ride it to glory, lol.
I am in the same boat as Lowman or I would be averaging down now. I don't have any unencumbered cash.
I think you are right. I hope so anyway. I got into this one pretty high a while back because I thought it was going to run then. Unfortunately it dropped instead. I am now averaged down and ready for a run this time.
Actually that is perfect. I am in ETIM, QBIT both and will likely do the same. I have options in HEPH but I want to be long this stock because I like what they are doing.
No problem. I wish you had been right the first time, lol. I am in the process of updating the ibox today. I hope to be able to summarize what is going on and put in some pertinent links.
I thought it was the Nov 31st but I hope it is the 1st. I will look into it today and try to update the ibox.
Yes, I am going to try and do that this weekend.
Yes, it will have it's day. This company has so much going on.